Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

BUSINESS COMBINATIONS (Tables)

v3.23.1
BUSINESS COMBINATIONS (Tables)
12 Months Ended
Dec. 31, 2022
Disclosure of detailed information about business combination [line items]  
Disclosure of detailed information about cash outflow/inflow on the acquisition [Table Text Block]
   
Fair value
 
   
TFC
   
MYM
   
Vironna
   
Pharm Yarok
   
Oranim
   
Panaxia
 

Assets

                                               
                                                 

Cash and cash equivalents

 

$

362    

$

131    

$

57    

$

105    

$

485    

$

-  
Trade and other receivables
   
3,240
     
2,548
     
259
     
456
     
1,329
     
-
 
Indemnification asset
   
8,131
     
-
     
-
     
-
     
-
     
-
 
Biological assets
   
785
     
63
     
-
     
-
     
-
     
-
 
Inventory
   
3,883
     
4,180
     
639
     
346
     
1,043
     
19
 
Loan receivable
   
8,470
     
2,122
     
-
     
-
     
-
     
-
 
Investments
   
-
     
-
     
-
     
-
     
-
     
2,837
 
Property, plant and equipment
   
15,193
     
6,105
     
210
     
1,145
     
389
     
88
 
Derivative assets
   
114
     
-
     
-
     
-
     
-
     
-
 
Right of use assets
   
15,037
     
630
     
-
     
-
     
1,312
     
-
 
Investments
   
319
     
-
     
-
     
-
     
-
     
-
 
Intangible assets
   
6,458
     
17,200
     
2,316
     
974
     
2,991
     
776
 
                                                 
Total identifiable assets
   
61,992
     
32,979
     
3,481
     
3,026
     
7,549
     
3,720
 
                                                 
Liabilities
                                               
                                                 
Trade and other payables
   
(15,196
)
   
(4,442
)
   
(854
)
   
(1,448
)
   
(1,777
)
   
-
 
Bank loans
   
-
     
(915
)
   
-
     
-
     
-
     
-
 
Lease liability
   
(15,037
)
   
(873
)
   
-
     
-
     
(1,312
)
   
-
 
Long term loans
   
-
     
-
     
-
     
(1,042
)
   
-
     
-
 
Deferred tax, net
   
-
     
(4,061
)
   
(532
)
   
(224
)
   
(688
)
   
-
 
                                                 
Total identifiable liabilities
   
(30,233
)
   
(10,291
)
   
(1,386
)
   
(2,714
)
   
(3,777
)
   
-
 
                                                 
Total identifiable assets, net
   
31,759
     
22,688
     
2,095
     
312
     
3,772
     
3,720
 
                                                 
Goodwill arising on acquisition
   
67,269
     
39,932
     
2,250
     
4,294
     
2,907
     
3,240
 
                                                 
Non-controlling interest
   
-
     
-
     
(1,026
)
   
-
     
(1,848
)
   
-
 
                                                 
Total purchase price
 
$
99,028
   
$
62,620
   
$
3,319
   
$
4,606
   
$
4,831
   
$
6,960
 
Disclosure Of Detailed Information About Fair Value Of The Identifiable Assets Acquired And Liabilities Assumed On Acquisition Date [Table Text Block]
   
Preliminary PPA
   
 
Adjustments
   
Final PPA
 
                   
Inventory
 
$
19
   
$
-
   
$
19
 
Advance payment for intangible assets of pharmacy
   
2,837
     
3,367
     
6,204
 
Property, plant and equipment
   
88
     
-
     
88
 
Intangible assets
   
776
     
(593
)
   
183
 
                         
Total identifiable assets
   
3,720
     
2,774
     
6,494
 
                         
Goodwill arising on acquisition
   
3,240
     
(2,774
)
   
466
 
                         
Total purchase price
 
$
6,960
   
$
-
   
$
6,960
 
Trichome Financial Corp. (“Trichome”) [Member]  
Disclosure of detailed information about business combination [line items]  
Disclosure of detailed information about business combinations [Table Text Block]
   
Proforma results
for the year ended December 31, 2021
   
         
Revenues
$
55,563  
         
Net loss
$
(25,372 )
MYM Nutraceuticals Inc. (“MYM”) [Member]  
Disclosure of detailed information about business combination [line items]  
Disclosure of detailed information about business combinations [Table Text Block]
 
   
Proforma results for the year ended December
31, 2021
   
   
Revenues

$

61,639
 
         
Net loss
$
(20,132

)

 

Pharm Yarok pharmacy [Member]  
Disclosure of detailed information about business combination [line items]  
Disclosure of detailed information about business combinations [Table Text Block]
 
   
Proforma results for the year
ended December 31, 2021
 
       
Revenues
 
$
58,345
 
         
Net loss
 
$
(18,986
)
Vironna pharmacy [Member]  
Disclosure of detailed information about business combination [line items]  
Disclosure of detailed information about business combinations [Table Text Block]
 
   
Proforma results
for the year
ended December
31, 2021
 
       
Revenues
 
$
56,816
 
         
Net loss
 
$
(18,180
)
Oranim pharmacy [Member]  
Disclosure of detailed information about business combination [line items]  
Disclosure of detailed information about business combinations [Table Text Block]
 
   
Proforma results
for the year
ended December 31, 2021
 
       
Revenues
 
$
67,589
 
         
Net loss
 
$
(17,870
)